Kapadia Sandip 4

What Happened
Sandip Kapadia, a director of Passage BIO, was granted a derivative award on 2026-05-19 covering 10,539 shares. The reported acquisition price is $0.00, indicating a stock option/award rather than an open-market purchase or sale. No cash was exchanged in this filing.

Key Details

• Transaction date: 2026-05-19. Filing date: 2026-05-21 (filed within the typical 2-business-day Form 4 window).
• Transaction type/code: Grant/Award (code A); derivative security (stock option/award).
• Amount: 10,539 shares; reported price: $0.00; reported dollar value: $0.
• Shares owned after transaction: not specified in the Form 4 filing.
• Footnote: The award vests in full on the earlier of (i) the one-year anniversary of the grant or (ii) the issuer's 2027 Annual Meeting of stockholders, subject to the reporting person’s continued service (per footnote F1).
• This is a grant of a derivative award (not an immediate market purchase or sale).

Context
This filing reports a compensation-related grant to a director. Such awards typically vest over time and do not represent an immediate cash investment or sale; they may lead to future dilution if exercised or settled. For retail investors, outright purchases or sales by insiders can be more directly informative about personal conviction than routine grants, which are common components of director compensation.